Yoon Ah Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yoon Ah Park has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Hee Cheol Kim
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
3 shared publications - Hyeong Rok Kim
Department of Surgery, Chonnam National University Hwasun Hospital and Medical School , Hwasun
2 shared publications - Seong Hyeon Yun
Department of Surgery; Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Republic of Korea
2 shared publications - Woo Yong Lee
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2 shared publications - Yong Beom Cho
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
2 shared publications - Hae Su Kim
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
1 shared publication
Latest Publications
- 23 September 2025
- Published by Springer Nature in European Radiology
- Vol. 36 (3) , 1864-1873
MRI features of lateral lymph nodes predicting lateral local recurrence and prognostic impact of lateral lymph node dissection in low rectal cancer
Objectives To evaluate MRI features of lateral lymph nodes (LLNs) associated with lateral local recurrence (LLR) and assess the prognostic value of lateral lymph node dissection (LLND) in low rectal cancer. Materials and methods This retrospective study included consecutive patients with cT3-4 rectal cancer located ≤ 8 cm from the anal verge who underwent radical surgery following neoadjuvant chemoradiotherapy. LLN location, short-axis diameter, and malignant features (internal heterogeneity or irregular borders) were assessed. LLR rates were estimated using Kaplan–Meier analysis and compared with the log-rank test. Cox proportional hazards models identified factors associated with LLR. Results A total of 878 patients (mean age, 57 ± 12 years; 574 males) were included. The cumulative 5-year LLR rate was 4.2%. Patients with LLNs ≥ 7 mm had higher LLR rates than those with LLNs < 7 mm or no LLNs (17.2% vs. 2.6% vs. 3.1% at 5 years, p < 0.001). Malignant features on pretreatment MRI were associated with higher LLR rates than LLNs without malignant features or no LLNs (28.2% vs. 2.6% vs. 3.1% at 5 years, p < 0.001). In multivariable analysis, malignant features remained independent predictors of LLR (hazard ratio = 9.0 [1.9–43.9], p = 0.006). LLND reduced LLR in patients with internal iliac lymph nodes with malignant features (14.2% vs. 52.9% at 5 years, p = 0.01). Conclusion Malignant features of LLNs on pretreatment MRI are associated with increased risk of LLR. LLND significantly reduces LLR in patients with internal iliac lymph nodes with malignant features. Key Points Question The optimal therapeutic approach for rectal cancer patients with abnormal lateral lymph nodes on the staging MRI remains controversial. Findings Malignant features in lateral lymph nodes independently predicted lateral local recurrence, and lateral lymph node dissection reduced recurrence for internal iliac lymph nodes with malignant features. Clinical relevance Identifying malignant features of lateral lymph nodes on pretreatment MRI enables risk stratification for lateral local recurrence and helps guide the need for lateral lymph node dissection, potentially improving oncologic outcomes in patients with low rectal cancer. Graphical Abstract
- 23 September 2025
- Published by Springer Nature in European Radiology
- Vol. 36 (3) , 1864-1873
MRI features of lateral lymph nodes predicting lateral local recurrence and prognostic impact of lateral lymph node dissection in low rectal cancer
Objectives To evaluate MRI features of lateral lymph nodes (LLNs) associated with lateral local recurrence (LLR) and assess the prognostic value of lateral lymph node dissection (LLND) in low rectal cancer. Materials and methods This retrospective study included consecutive patients with cT3-4 rectal cancer located ≤ 8 cm from the anal verge who underwent radical surgery following neoadjuvant chemoradiotherapy. LLN location, short-axis diameter, and malignant features (internal heterogeneity or irregular borders) were assessed. LLR rates were estimated using Kaplan–Meier analysis and compared with the log-rank test. Cox proportional hazards models identified factors associated with LLR. Results A total of 878 patients (mean age, 57 ± 12 years; 574 males) were included. The cumulative 5-year LLR rate was 4.2%. Patients with LLNs ≥ 7 mm had higher LLR rates than those with LLNs < 7 mm or no LLNs (17.2% vs. 2.6% vs. 3.1% at 5 years, p < 0.001). Malignant features on pretreatment MRI were associated with higher LLR rates than LLNs without malignant features or no LLNs (28.2% vs. 2.6% vs. 3.1% at 5 years, p < 0.001). In multivariable analysis, malignant features remained independent predictors of LLR (hazard ratio = 9.0 [1.9–43.9], p = 0.006). LLND reduced LLR in patients with internal iliac lymph nodes with malignant features (14.2% vs. 52.9% at 5 years, p = 0.01). Conclusion Malignant features of LLNs on pretreatment MRI are associated with increased risk of LLR. LLND significantly reduces LLR in patients with internal iliac lymph nodes with malignant features. Key Points Question The optimal therapeutic approach for rectal cancer patients with abnormal lateral lymph nodes on the staging MRI remains controversial. Findings Malignant features in lateral lymph nodes independently predicted lateral local recurrence, and lateral lymph node dissection reduced recurrence for internal iliac lymph nodes with malignant features. Clinical relevance Identifying malignant features of lateral lymph nodes on pretreatment MRI enables risk stratification for lateral local recurrence and helps guide the need for lateral lymph node dissection, potentially improving oncologic outcomes in patients with low rectal cancer. Graphical Abstract
- 1 October 2017
- Published by Elsevier in Archives of Physical Medicine and Rehabilitation
- Vol. 98 (10) , e113
Symptoms and Muscle Size Change After Pelvic Floor Exercise in Rectosigmoid Cancer Patients with LARS
- 1 October 2017
- Published by Elsevier in Archives of Physical Medicine and Rehabilitation
- Vol. 98 (10) , e113
Symptoms and Muscle Size Change After Pelvic Floor Exercise in Rectosigmoid Cancer Patients with LARS
- Open Access
- 18 February 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 120
The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis
KRAS mutations are common in colorectal cancer (CRC). The role of KRAS mutation status as a prognostic factor remains controversial, and most large population-based cohorts usually consist of patients with non-metastatic CRC. We evaluated the impact of KRAS mutations on the time to recurrence (TTR) and overall survival (OS) in patients with metastatic CRC who underwent curative surgery with perioperative chemotherapy. Patients who underwent curative resection for primary and synchronous metastases were retrospectively collected in a single institution during a 6 year period between January 2008 and June 2014. Patients with positive surgical margins, those with known BRAF mutation, or those with an unknown KRAS mutation status were excluded, and a total of 82 cases were identified. The pathological and clinical features were evaluated. Patients’ outcome with KRAS mutation status for TTR and OS were investigated by univariate and multivariate analysis. KRAS mutations were identified in 37.8 % of the patients and not associated with TTR or OS between KRAS wild type and KRAS mutation cohorts (log-rank p = 0.425 for TTR; log-rank p = 0.137 for OS). When patients were further subdivided into three groups according to mutation subtype (wild-type vs. KRAS codon 12 mutation vs. KRAS codon 13 mutation) or amino acid missense mutation type (G > A vs. G > T vs. G > C), there were no significant differences in TTR or OS. Mutational frequencies were significantly higher in patients with lung metastases compared with those with liver and ovary/bladder metastases (p = 0.039), however, KRAS mutation status was not associated with an increased risk of relapsed in the lung. KRAS mutation was not associated with TTR or OS in patients with metastatic CRC who underwent curative surgery with perioperative chemotherapy.
- 18 February 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 120
Open AccessThe impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis
KRAS mutations are common in colorectal cancer (CRC). The role of KRAS mutation status as a prognostic factor remains controversial, and most large population-based cohorts usually consist of patients with non-metastatic CRC. We evaluated the impact of KRAS mutations on the time to recurrence (TTR) and overall survival (OS) in patients with metastatic CRC who underwent curative surgery with perioperative chemotherapy. Patients who underwent curative resection for primary and synchronous metastases were retrospectively collected in a single institution during a 6 year period between January 2008 and June 2014. Patients with positive surgical margins, those with known BRAF mutation, or those with an unknown KRAS mutation status were excluded, and a total of 82 cases were identified. The pathological and clinical features were evaluated. Patients’ outcome with KRAS mutation status for TTR and OS were investigated by univariate and multivariate analysis. KRAS mutations were identified in 37.8 % of the patients and not associated with TTR or OS between KRAS wild type and KRAS mutation cohorts (log-rank p = 0.425 for TTR; log-rank p = 0.137 for OS). When patients were further subdivided into three groups according to mutation subtype (wild-type vs. KRAS codon 12 mutation vs. KRAS codon 13 mutation) or amino acid missense mutation type (G > A vs. G > T vs. G > C), there were no significant differences in TTR or OS. Mutational frequencies were significantly higher in patients with lung metastases compared with those with liver and ovary/bladder metastases (p = 0.039), however, KRAS mutation status was not associated with an increased risk of relapsed in the lung. KRAS mutation was not associated with TTR or OS in patients with metastatic CRC who underwent curative surgery with perioperative chemotherapy.
- 1 September 2014
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 57 (9) , 1049-1058
The Role of Palliative Resection for Asymptomatic Primary Tumor in Patients With Unresectable Stage IV Colorectal Cancer
The prognostic role of surgical resection of primary tumors is not well established in patients with asymptomatic unresectable stage IV colorectal cancer. The aims of this study were to reveal the prognostic role of surgical resection of primary tumors and to define prognostic factors affecting long-term oncological outcomes in patients with asymptomatic unresectable synchronous metastases. This study was a retrospective analysis of prospectively collected data. Between 2000 and 2008, a total of 416 patients with asymptomatic unresectable stage IV colorectal cancer were analyzed with propensity score matching. Prematching baseline characteristics were compared by bivariate analysis, and 113 pairs were selected after 1:1 matching with propensity scores estimated from logistic regression. The primary end point was overall survival. Among 416 patients, 218 (52.4%) underwent palliative resection of the primary tumor. Before propensity score matching, palliative resection resulted in a better survival rate than nonresection in univariate analysis (p < 0.001), but not in multivariate analysis (p = 0.08). After matching, the 5-year overall survival rate was significantly lower for patients with peritoneal metastasis and clinical M1b stage tumors in univariate analysis (p = 0.004 and p = 0.02). However, neither peritoneal metastasis nor clinical M1b stage showed any prognostic significance in multivariate analysis. The overall 5-year survival rate of the postmatching group was 4.9% and 3.5% in the palliative resection and nonresection groups. Consequently, palliative resection was not associated with a significant increase in survival compared with nonresection (p = 0.27). A subgroup analysis performed according to the site of metastasis also did not show any significant survival benefit of palliative resection after matching. Selection bias and potential confounders were limitations of this study. Resection of the primary tumor in patients with asymptomatic unresectable stage IV colorectal cancer was not associated with an improvement in overall survival after propensity score matching.
- 1 September 2014
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 57 (9) , 1049-1058
The Role of Palliative Resection for Asymptomatic Primary Tumor in Patients With Unresectable Stage IV Colorectal Cancer
The prognostic role of surgical resection of primary tumors is not well established in patients with asymptomatic unresectable stage IV colorectal cancer. The aims of this study were to reveal the prognostic role of surgical resection of primary tumors and to define prognostic factors affecting long-term oncological outcomes in patients with asymptomatic unresectable synchronous metastases. This study was a retrospective analysis of prospectively collected data. Between 2000 and 2008, a total of 416 patients with asymptomatic unresectable stage IV colorectal cancer were analyzed with propensity score matching. Prematching baseline characteristics were compared by bivariate analysis, and 113 pairs were selected after 1:1 matching with propensity scores estimated from logistic regression. The primary end point was overall survival. Among 416 patients, 218 (52.4%) underwent palliative resection of the primary tumor. Before propensity score matching, palliative resection resulted in a better survival rate than nonresection in univariate analysis (p < 0.001), but not in multivariate analysis (p = 0.08). After matching, the 5-year overall survival rate was significantly lower for patients with peritoneal metastasis and clinical M1b stage tumors in univariate analysis (p = 0.004 and p = 0.02). However, neither peritoneal metastasis nor clinical M1b stage showed any prognostic significance in multivariate analysis. The overall 5-year survival rate of the postmatching group was 4.9% and 3.5% in the palliative resection and nonresection groups. Consequently, palliative resection was not associated with a significant increase in survival compared with nonresection (p = 0.27). A subgroup analysis performed according to the site of metastasis also did not show any significant survival benefit of palliative resection after matching. Selection bias and potential confounders were limitations of this study. Resection of the primary tumor in patients with asymptomatic unresectable stage IV colorectal cancer was not associated with an improvement in overall survival after propensity score matching.
- 13 March 2014
- Published by Wiley in Journal of Surgical Oncology
- Vol. 109 (8) , 848-852
Mismatch repair system and p53 expression in patients with T1 and T2 colorectal cancer: Predictive role of lymph node metastasis and survival
Background The aim of this study was to evaluate the predictive role of the mismatch repair (MMR) system and p53 expression for lymph node metastasis and long-term survival in patients with T1 and T2 colorectal cancer. Methods A total of 543 patients with T1 or T2 colorectal cancers who underwent radical surgery with regional lymphadenectomy from December 2007 to December 2009 were analyzed. Predictive factors for lymph node metastasis and prognostic factors were analyzed. Results During the median follow-up period of 4 years, the 5-year disease-free survival rate for patients without lymph node metastasis was 94.8%, which was significantly higher than that for those with lymph node metastases (85.2%; P < 0.001). On multivariate analysis, gender, tumor location, N category, lymphatic invasion, vascular invasion, and perineural invasion were independent prognostic factors for disease-free survival; however MMR defect, p53 expression, and microsatellite instability (MSI) were not. The presence of lymphatic invasion, vascular invasion, and tumor budding were independent predictors of lymph node metastasis. Conclusions In patients with T1 or T2 colorectal cancer, lymphatic invasion, vascular invasion, and tumor budding were predictive of lymph node metastasis; however, MMR defect, p53 expression, and MSI were not predictive. J. Surg. Oncol. 2014 109:848–852.
- 13 March 2014
- Published by Wiley in Journal of Surgical Oncology
- Vol. 109 (8) , 848-852
Mismatch repair system and p53 expression in patients with T1 and T2 colorectal cancer: Predictive role of lymph node metastasis and survival
Background The aim of this study was to evaluate the predictive role of the mismatch repair (MMR) system and p53 expression for lymph node metastasis and long-term survival in patients with T1 and T2 colorectal cancer. Methods A total of 543 patients with T1 or T2 colorectal cancers who underwent radical surgery with regional lymphadenectomy from December 2007 to December 2009 were analyzed. Predictive factors for lymph node metastasis and prognostic factors were analyzed. Results During the median follow-up period of 4 years, the 5-year disease-free survival rate for patients without lymph node metastasis was 94.8%, which was significantly higher than that for those with lymph node metastases (85.2%; P < 0.001). On multivariate analysis, gender, tumor location, N category, lymphatic invasion, vascular invasion, and perineural invasion were independent prognostic factors for disease-free survival; however MMR defect, p53 expression, and microsatellite instability (MSI) were not. The presence of lymphatic invasion, vascular invasion, and tumor budding were independent predictors of lymph node metastasis. Conclusions In patients with T1 or T2 colorectal cancer, lymphatic invasion, vascular invasion, and tumor budding were predictive of lymph node metastasis; however, MMR defect, p53 expression, and MSI were not predictive. J. Surg. Oncol. 2014 109:848–852.